ICICI Direct Broker Research reports

Q2FY26 Performance: Patel Engineering reported consolidated revenue of 1208.4 crore, up 2.9% YoY, due to subdued execution. Operating EBITDA came in at 159 crore with EBITDA margin at 13.1%, down 27 bps YoY. PAT stood at 73 crore, flat YoY, also affected due to provision of 31 crore made for settlement of claim,...

Metering & systems segment contributed ~53% to total revenues as of H1FY26, while balance ~47% by consumer & industrials. Company has 7 manufacturing facilities (5 in Haryana & 2 in Himachal) and 2 R&D centres....

Q2FY26 Performance: Ahluwalia Contracts reported consolidated revenue from operations of 1,177 crore in Q1FY26, up 16.4% YoY, driven by healthy execution. EBITDA came in at 128.6 crore, up 75.2% YoY, with an EBITDA margin of 10.9%, up 367 bps YoY, on a benign base. Reported PAT stood at 79 crore, up 106.1%...

Strong Q2; Margin to expand by 200bps in FY27 Q2FY26 performance: India business grew by 35% YoY driven by mix of volume and price led growth. Volume growth stood at 7% YoY continuing its positive growth trajectory for 10th consecutive quarter. International business grew by 20% YoY on constant currency basis. Inflated copra prices (+113% YoY) and high base led to 814bps YoY decline in gross margins to 42.6%. EBIDTA margins declined by...

Q2FY26- Revenues growth a little subdued but margins strongRevenues grew ~9% YoY to 2556.5 crore driven by both domestic formulations and API exports. Domestic formulations grew 8% YoY to 1019 crore, driven by strong traction in pain management but also had some impact on account of GST rate rationalization. Export APIs grew ~45% to 221 crore. Under exports formulations - Branded exports grew ~2% to 145 crore, Institutional exports de-grew 29% YoY to 79.7 crore and generic exports de-grew 6% YoY to 268 crore. EBITDA grew 23.4% YoY to 545 crore while EBITDA margins grew by 257 bps to 21.3% aided...

The YoY numbers for the quarter are not comparable due to low base of FY25. Post the Gagillapur USFDA warning letter, the company has focused on developing other facilities and also focused on incremental flings across markets. Besides CNS and ADHD, it is also focusing on Oncology as a segment with dedicated API and formulations block at Vizag. The management expects full revival of Gagillapur facility post clearance from the USFDA (Management meeting with USFDA scheduled in Jan 26) by filing new products. On the margins front, the numbers continued to...

About the stock: Mishra Dhatu Nigam (Midhani) is one of the key manufacturers of critical metals such as special steels, super alloys (nickel base, iron base and cobalt base), titanium alloys etc. The company primarily cater to the requirements...

About the stock: Engineers India (EIL), established in 1965, is an Indian public sector Navratna company, primarily present into two segments - Engineering Consultancy and LSTK (Lump Sum Turnkey). EIL's business operations span the hydrocarbon value chain as well as diversified areas of Metallurgy, Infrastructure, Bio Fuels & Green Hydrogen. The company is also present in international markets...

Q2FY26 Performance: PNC Infratech reported a muted performance in Q2FY26, with standalone revenue from operations at 983 crore, down 14.5% YoY, impacted by a weak executable order book as delay in appointed dates in 4 projects impacted...

Well placed to fund HAM equity: The total equity requirement for 11 HAM projects stands at 1,709 crore, of which 1,165 crore has already been infused as of September 2025. With a major portion already funded and additional liquidity expected from upcoming asset monetization (1,384 crore in net cash proceeds for equity investment, likely to complete by FY26 end), the...